Skip to main
CNTX

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics Inc is advancing its pipeline of therapies aimed at treating solid tumors, specifically focusing on female, hormone-dependent cancers, with promising early data emerging from its preclinical program, CTIM-76. The company's strong cash position, which extends into 2027, supports the continued enrollment and evaluation of CTIM-76 across multiple solid tumor types, indicating multiple clinical, regulatory, and data-driven value catalysts in the upcoming year. Furthermore, the early signs of clinical activity and a favorable safety profile for CTIM-76 in heavily pre-treated patients suggest a potential de-risking of the program, which could enhance investor interest and attract potential partnerships prior to the availability of more traditional efficacy data.

Bears say

Context Therapeutics experienced a reduction in research and development expenses in Q3 2025, reporting $8.7 million compared to $16.8 million in the same quarter of the previous year, which may signal a reduction in pipeline advancement or challenges within their clinical programs. Despite this decrease in R&D spending leading to a net loss of $9.7 million—improved from $17.5 million in the previous year—the company is facing significant risks, including the need for approximately $250 million in additional financing through 2041 and potential regulatory hurdles. Furthermore, ongoing concerns regarding safety signals, efficacy levels of their treatments, and competition from existing therapies heighten the uncertainty surrounding the company's future performance and financial stability.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Feb 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.